Incyte Corporation (NASDAQ:INCY) headquartered in Wilmington, will host a conference call for the investment community to discuss the 3Q20 earnings result on 5th November 2020 at 8:00 AM Eastern Time.
Those interested in listening to the conference call live via the Internet can visit www.incyte.com
Earnings Expectation
Incyte Corporation proprietary therapeutics in oncology, is expected to report third quarter earnings results, before market open, on Thursday 5th November 2020. Analysts polled by Thomson Reuters anticipate third quarter income of $ 0.75 per share from revenue of $ 623.31 million. Looking ahead, the full year loss are expected at $ 0.06 per share on the revenues of $ 2537.31 million.
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug in Phase III clinical trial for steroid-refractory acute graft-versus-host-diseases (GVHD); and Phase II trial for the treatment of essential thrombocythemia and refractory myelofibrosis.
